News

Clinical Trials Arena on MSN3d
First subject dosed in Vantage’s Phase II trial for diabetic retinopathy
Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...
Medscape1y
Diabetic Retinopathy Management Guidelines
Diabetic retinopathy ... PDR: Proliferative DR; RCO: Royal College of Ophthalmologists. NHMRC Dilated ophthalmoscopy or slit-lamp biomicroscopy (dilated) with a lens or photography (non-mydriatic ...
Business Insider6d
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy
an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of ...
Medical Dialogues12d
Glycemic Variability Marker Linked To Higher Neovascular Glaucoma Risk In Proliferative Diabetic Retinopathy Patients: Study
Researchers have observed in a new study that stress hyperglycemia (SHR) ratio could be a useful predictor of neovascular ...
PharmiWeb9d
Diabetic Retinopathy Market Size to Cross $15.1 Billion by 2035
The global Diabetic Retinopathy Market is valued at USD 9.1 Billion in 2024 and is projected to reach a value of USD 15.1 ...